No Data
Tai Mei Medical Technology (02576) announced its performance for the 2024 fiscal year, with a loss attributable to Shareholders of 0.215 billion yuan, a year-on-year decrease of 38.11%.
Tai Mei Medical Technology (02576) announced its annual results for the year ending December 31, 2024, during which the group achieved...
Tai Mei Medical Technology (02576.HK) announced its annual performance with a significant increase in gross margin and a substantial reduction in losses year-on-year.
On March 24, Gelonghui announced that Taimei Medical Technology (02576.HK) focuses on core competitive products and aims to enhance internal Operation efficiency and profitability for the fiscal year 2024. Throughout 2024, the overall Business remains stable, and the gross margin significantly improves, with net losses and adjusted net losses substantially narrowing compared to the same period last year. In 2024, the group's total revenue reached RMB 551.2 million, with the gross margin rising from 31.2% in 2023 to 40.8%, an increase of 9.6 percentage points, showcasing a significant improvement in gross margin. The company's annual loss decreased from the previous year's figures.
Express News | Zhejiang Taimei Medical Technology - FY Loss RMB217.4 Mln
TAIMEI TECH: ANNOUNCEMENT OF THE RESULTSFOR THE YEAR ENDED DECEMBER 31, 2024
Tai Mei Medical Technology (02576.HK): Ni Xiaomei and Feng Zhiwei have been appointed as members of the Board of Directors Nomination Committee.
Gelonghui, on March 24, announced that Taimei Medical Technology (02576.HK) has, as of March 24, 2025, appointed executive director Ni Xiaomei and independent non-executive director Feng Zhiwei as members of the Board of Directors Nomination Committee, effective from March 24, 2025.
Tai Mei Medical Technology (02576.HK) plans to hold a Board of Directors meeting on March 24 to approve the annual performance.
Glory Holdings announced on March 11 that Taimei Medical Technology (02576.HK) will hold a Board of Directors meeting on March 24, 2025 (Monday) to discuss and approve the group's full-year performance ending December 31, 2024, and its announcement, as well as review the proposal for the distribution of a final dividend (if any).
